IP Library › Granted Patent US 11,135,167
Granted Patent B2
US 11,135,167 · App. 16/516,931 · Granted Oct 5, 2021

Polymer particles

Inventors: Gregory M. Cruise (Rancho Santa Margarita, CA); Gloria Hincapie (Aliso Viejo, CA); Clayton Harris (Aliso Viejo, CA)
Assignee: Terumo Corporation
A61K9/1635A61K9/0029A61L24/001A61L24/06A61L31/048C08F220/38C08F220/56A61K9/19A61L2430/36C08F220/382C08F222/1006C08F222/385C08F222/408C08L33/02C08L33/14C08L33/26C08L2203/02C08L2312/00Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,135,167
App. No.
16/516,931
Granted
Oct 5, 2021
Kind
B2
Abstract

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

Claims (28)

1. An embolic solution including:

1) polymer particles formed from a solution including at least one negatively charged monomer including at least one functional group, and at least one crosslinker; and at least one positively charged drug; or

2) polymer particles formed from a solution including at least one positively charged monomer including at least one functional group, and at least one crosslinker; and at least one negatively charged drug;

wherein the polymer particles have a spherical diameter between about 40 μm and about 1,200 μm.

2. The embolic solution of claim 1 , wherein the polymer particles are susceptible to degradation through hydrolysis or enzymatic action, and wherein the degradation provides less than about 10% of the polymer particles intact after about 5 days.

3. The embolic solution of claim 1 , wherein the spherical diameter is between about 75 μm and about 1,200 μm.

4. The embolic solution of claim 1 , wherein the crosslinker includes at least two functional groups.

5. The embolic solution of claim 1 , wherein the crosslinker includes at least one linkage susceptible to degradation through hydrolysis or enzymatic action.

6. The embolic solution of claim 1 , wherein the at least one crosslinker is bis-glycidyl amino alcohol,

wherein a, b, c, d, e, and f are each independently 1-20.

7. The embolic solution of claim 5 , wherein the at least one linkage is an ester, a thioester, a carbonate, a peptide cleavable by matrix metalloproteinases, a peptide cleavable by matrix collagenases, a peptide cleavable by matrix elastases, a peptide cleavable by matrix cathepsins, or a combination thereof.

8. The embolic solution of claim 1 , wherein the crosslinker is bis-glycidyl amino alcohol or bi-functionalized methacryloyl-Ala-Pro-Gly-Leu-AEE-methacrylate.

9. The embolic solution of claim 1 , including:

polymer particles formed from a solution including at least one negatively charged monomer including at least one functional group, and at least one crosslinker; and

at least one positively charged drug.

10. The embolic solution of claim 9 , wherein the at least one negatively charged monomer includes an acidic moiety.

11. The embolic solution of claim 9 , wherein the at least one negatively charged monomer includes a carboxylic acid.

12. The embolic solution of claim 10 , wherein the at least one negatively charged monomer is acrylic acid, methacrylic acid, 3-sulfopropyl acrylate, 3-sulfopropyl methacrylate, a derivative thereof, a combination thereof, or a salt thereof.

13. The embolic solution of claim 1 , including:

polymer particles formed from a solution including at least one positively charged monomer including at least one functional group, and at least one crosslinker; and

at least one negatively charged drug.

14. The embolic solution of claim 13 , wherein the at least one positively charged monomer includes a basic moiety.

15. The embolic solution of claim 14 , wherein the at least one positively charged monomer includes an amine.

16. The embolic solution of claim 14 , wherein the at least one positively charged monomer is amino ethyl methacrylate, aminopropyl methacrylate, a derivative thereof, a combination thereof, or a salt thereof.

17. The embolic solution of claim 1 , wherein the composition is sterilized.

18. The embolic solution of claim 1 including a radiopaque contrast agent.

19. The embolic solution of claim 1 including a dye.

20. The embolic solution of claim 1 , wherein the polymer particles have a circularity greater than about 0.9.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2019
From: CRUISE, GREGORY M.; HINCAPIE, GLORIA; HARRIS, CLAYTON
To: MICROVENTION, INC.
Reel/Frame 049805/0098 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2019
From: MICROVENTION, INC.
To: TERUMO CORPORATION
Reel/Frame 049806/0223 →
Continuity (7)
Continuation 16175609 · Oct 30, 2018
Continuation 15910976 · Mar 2, 2018
Continuation 15630048 · Jun 22, 2017
Continuation 15369213 · Dec 5, 2016
Continuation 14491776 · Sep 19, 2014
Provisional Application 61880036 · Sep 19, 2013
Related Publication 20190338059A1 · Nov 7, 2019
Cited By (2)
US 12,364,786 US 12,447,228